A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Lymphoma, Mantle-Cell Interventions: Drug: Zanubrutinib; Drug: Rituximab; Drug: Bendamustin Sponsors: Ruijin Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials